Drugs in Development for Malaria.
Drugs in Development for Malaria.
复制标题
DOI：
10.1007/s40265-018-0911-9
复制
发表时间：
2018-06
期刊：
影响因子：
11.5
通讯作者：
Phyo AP
中科院分区：
文献类型：
--
作者：
Ashley EA;Phyo AP
在过去的二十年里，随着产品开发伙伴关系发挥了主导作用，抗疟疾药物的开发激增。东南亚恶性疟原虫对青蒿素衍生物、哌喹和甲氟喹的抗药性意味着迫切需要新的抗疟疾药物。至少有13种药物正在进行临床开发。其中大多数是用于治疗简单恶性疟疾的血液分裂药，正在单独或作为两种药物组合的一部分进行评估。取得进展的领先候选者是Artefenomel-Fequine和Lumefantrine-KAF156，这两个项目都处于2b期。严重疟疾的治疗仍然依赖两种由来已久的非肠道药物：青蒿琥酯和奎宁，七叶肝素被评估为辅助治疗。他苯喹正在接受严格监管机构的审查，以获得批准作为预防间日疟原虫复发的单剂治疗。这比标准的14天伯氨喹方案有了进步；然而，葡萄糖-6-磷酸脱氢酶缺乏症患者发生急性溶血性贫血的风险仍然存在。在疾病预防方面，几种较新的药物显示出潜力，但在几年内不太可能被推荐用于孕妇和幼儿这一主要目标群体。最新预测显示，疟疾负担在未来几十年将继续居高不下。这一事实，再加上抗疟疾药物由于耐药性的反复丧失，表明未来几年将需要新的抗疟疾药物。东南亚基于青蒿素的联合疗法的失败促使人们重新评估目前的疟疾联合疗法，将三种或三种以上药物纳入正在考虑的单一疗法中。
The last two decades have seen a surge in antimalarial drug development with product development partnerships taking a leading role. Resistance of Plasmodium falciparum to the artemisinin derivatives, piperaquine and mefloquine in Southeast Asia means new antimalarials are needed with some urgency. There are at least 13 agents in clinical development. Most of these are blood schizonticides for the treatment of uncomplicated falciparum malaria, under evaluation either singly or as part of two-drug combinations. Leading candidates progressing through the pipeline are artefenomel–ferroquine and lumefantrine-KAF156, both in Phase 2b. Treatment of severe malaria continues to rely on two parenteral drugs with ancient forebears: artesunate and quinine, with sevuparin being evaluated as an adjuvant therapy. Tafenoquine is under review by stringent regulatory authorities for approval as a single-dose treatment for Plasmodium vivax relapse prevention. This represents an advance over standard 14-day primaquine regimens; however, the risk of acute haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase deficiency remains. For disease prevention, several of the newer agents show potential but are unlikely to be recommended for use in the main target groups of pregnant women and young children for some years. Latest predictions are that the malaria burden will continue to be high in the coming decades. This fact, coupled with the repeated loss of antimalarials to resistance, indicates that new antimalarials will be needed for years to come. Failure of the artemisinin-based combinations in Southeast Asia has stimulated a reappraisal of current approaches to combination therapy for malaria with incorporation of three or more drugs in a single treatment under consideration.
登录
查看更多内容
与柬埔寨恶性疟原虫疟疾双氢青蒿素-哌喹失败相关的遗传标记：基因型-表型关联研究。
DOI：
10.1016/s1473-3099(16)30409-1
发表时间：
2017-03
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Amato R;Lim P;Miotto O;Amaratunga C;Dek D;Pearson RD;Almagro-Garcia J;Neal AT;Sreng S;Suon S;Drury E;Jyothi D;Stalker J;Kwiatkowski DP;Fairhurst RM
通讯作者：
Fairhurst RM
影响因子：
5.7
作者：
Alout H;Foy BD
通讯作者：
Foy BD
DOI：
10.1073/pnas.1414221111
发表时间：
2014-12-16
影响因子：
11.1
作者：
Belen Jimenez-Diaz, Maria;Ebert, Daniel;Guy, R. Kiplin
通讯作者：
Guy, R. Kiplin
影响因子：
6.7
作者：
Barnes, Karen I.;Little, Francesca;White, Nicholas J.
通讯作者：
White, Nicholas J.
影响因子：
15.8
作者：
Achan, Jane;Adam, Ishag;Zongo, Issaka
通讯作者：
Zongo, Issaka